Stock analysts at StockNews.com initiated coverage on shares of iBio (NYSEAMERICAN:IBIO – Get Free Report) in a note issued to investors on Wednesday. The firm set a “sell” rating on the stock.
iBio Stock Performance
iBio stock opened at $4.06 on Wednesday. iBio has a one year low of $1.02 and a one year high of $49.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.91 and a quick ratio of 0.91.
iBio (NYSEAMERICAN:IBIO – Get Free Report) last released its earnings results on Friday, February 9th. The company reported ($2.42) EPS for the quarter.
iBio Company Profile
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
Further Reading
- Five stocks we like better than iBio
- P/E Ratio Calculation: How to Assess Stocks
- 3 Value Stocks Too Small For Buffett’s Portfolio
- What Are Dividend Contenders? Investing in Dividend Contenders
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- What Are Trending Stocks? Trending Stocks Explained
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
